TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27439448

Group type: EXPERIMENTAL
Intervention: CYP2B6*1/*1
Number of subjects: 36

Group type: COMPARATOR
Intervention: CYP2B6*1/*6
Number of subjects: 36

Group type: COMPARATOR
Intervention: CYP2B6*6/*6
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: POR rs2868177 AA homozygotes
Number of subjects: 36

Group type: COMPARATOR
Intervention: POR rs2868177 AG heterozygotes
Number of subjects: 36

Group type: COMPARATOR
Intervention: POR rs2868177 GG homozygotes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: POR rs2868177 AG heterozygotes in CYP2B6*1/*1
Number of subjects: 36

Group type: COMPARATOR
Intervention: POR rs2868177 AA homozygotes in CYP2B6*1/*1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: POR rs2868177 GG homozygotes in CYP2B6*6
Number of subjects: 36

Group type: COMPARATOR
Intervention: POR rs2868177 AA homozygotes in CYP2B6*6
Number of subjects: 36
Study: 24070326

Group type: EXPERIMENTAL
Intervention: Auricular acupressure with Sinapsis alba seeds
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 22373563

Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy (BCT)
Number of subjects: 868
Study: 20850556

Group type: EXPERIMENTAL
Intervention: Cortisol (2mg IV infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (IV infusion)
Number of subjects: 24
Study: 17438179

Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream applied twice a day for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (vehicle cream) applied twice a day for 4 weeks
Number of subjects: 12
Study: 16083542

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day
Number of subjects: 994

Group type: COMPARATOR
Intervention: Donepezil 5-10 mg/day
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 994

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 994
Study: 12196335

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 23
Study: 10337433

Group type: EXPERIMENTAL
Intervention: Olopatadine ophthalmic solution (0.1%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketorolac ophthalmic solution (0.5%)
Number of subjects: 0
Study: 7586946

Group type: EXPERIMENTAL
Intervention: Felbamate 2400 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 0
Study: 2180748

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (low dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no methylprednisolone)
Number of subjects: 32
Study: 7370142

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.08 mg kg‐1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Metocurine 0.4 mg kg‐1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Tubocurarine 0.4 mg kg‐1
Number of subjects: 26
Study: 29560806

Group type: EXPERIMENTAL
Intervention: Iranian pop music
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Traditional music
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mozart's classical music
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 64
Study: 29553889

Group type: EXPERIMENTAL
Intervention: Groups collectively low in testosterone
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Groups collectively high in testosterone
Number of subjects: 74
Study: 25867005

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 5 hours per week, 12 hours total training per week, 6-10 × 10-30 seconds maximal effort with 2-4 minutes rest
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CON) - 1 hour of HIT, 35 km total distance per week, 12 hours total training per week
Number of subjects: 41
Study: 24689367

Group type: EXPERIMENTAL
Intervention: Prostaglandin derivatives during the proliferative phase
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conventional hormone replacement cycle without prostaglandin
Number of subjects: 135
Study: 22816797

Group type: EXPERIMENTAL
Intervention: PaJR intervention with lay care guides and predictive modeling
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: PaJR intervention with lay care guides
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: PaJR intervention with predictive analytics
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 214
Study: 21176144

Group type: EXPERIMENTAL
Intervention: Alternative therapy (drotrecogin alfa at 24/30/36 μg/kg/hr for 48 to 168 hours)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Standard therapy (drotrecogin alfa at 24 μg/kg/hr infusion for 96 hours)
Number of subjects: 557
Study: 18255347

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with stent placement
Number of subjects: 48

Group type: COMPARATOR
Intervention: Biliary stents alone (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 48
Study: 16182683

Group type: EXPERIMENTAL
Intervention: Controlled sleep restriction with hypnotic administration in the first week
Number of subjects: 6
Study: 12634619

Group type: EXPERIMENTAL
Intervention: TLC D‐99 (60 mg/m2) with cyclophosphamide (600 mg/m2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional doxorubicin (60 mg/m2) with cyclophosphamide (600 mg/m2)
Number of subjects: 20
Study: 10790679

Group type: EXPERIMENTAL
Intervention: Non-parametric analysis of covariance methods
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Proportional hazards regression models
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Product-limit estimators of cumulative survival
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Stratified logrank tests
Number of subjects: 722
Study: 8879472

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron, p.o.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1947853

Group type: COMPARATOR
Intervention: Oral alphacalcidol (1 microgram daily) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous alphacalcidol for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alphacalcidol in euparathyroid subjects
Number of subjects: 0
Study: 6830658

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pirbuterol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amrinone + Isosorbide Dinitrate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pirbuterol + Isosorbide Dinitrate
Number of subjects: 13
Study: 31481572

Group type: EXPERIMENTAL
Intervention: Population-level care coordination initiative
Number of subjects: 250

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 250
Study: 28985891

Group type: EXPERIMENTAL
Intervention: Three-step method for modular lymphadenectomy (TSMML)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Conventional method for lymphadenectomy (CML)
Number of subjects: 270
Study: 26872076

Group type: EXPERIMENTAL
Intervention: Bipolar plasma vaporization
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cold-knife urethrotomy
Number of subjects: 53
Study: 25226360

Group type: EXPERIMENTAL
Intervention: Continuous ventilation during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonventilated group
Number of subjects: 30
Study: 22908151

Group type: EXPERIMENTAL
Intervention: Omadacycline (100 mg i.v. QD, option to transition to 200 mg orally QD)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Linezolid (600 mg i.v. BID, option to transition to 600 mg orally BID)
Number of subjects: 111
Study: 20004445

Group type: EXPERIMENTAL
Intervention: Restricted intravenous fluid regimen adjusted by serum lactate level (group A)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Restricted intravenous fluid regimen (group R)
Number of subjects: 299
Study: 17363763

Group type: EXPERIMENTAL
Intervention: Independent self-construal with promotion focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interdependent self-construal with prevention focus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cultural orientation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-construal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regulatory focus
Number of subjects: 0
Study: 15569656

Group type: EXPERIMENTAL
Intervention: Fibre-supplemented enteral feeding
Number of subjects: 172

Group type: COMPARATOR
Intervention: No fibre enteral feeding
Number of subjects: 172
Study: 12191979

Group type: EXPERIMENTAL
Intervention: Predialysis blood urea nitrogen concentrations peaked in March, coinciding with peak protein catabolic rates, protein and energy intakes.
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Predialysis systolic and diastolic BP values were highest in winter and lowest in summer.
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Mean predialysis hematocrit values were highest in July.
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Thirteen of the 21 variables examined demonstrated statistically significant seasonal components.
Number of subjects: 1445
Study: 9784272

Group type: EXPERIMENTAL
Intervention: Grouping strategy (Test 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (repeated task without grouping)
Number of subjects: 16
Study: 7882110

Group type: EXPERIMENTAL
Intervention: Endurance or resistance training exercise classes, 3 times per week for 3 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 41
Study: 2686760

Group type: EXPERIMENTAL
Intervention: DGAVP (des‐glycinamide‐arginine‐8‐vasopressin), 60 IU intranasally
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1103205

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 18
Study: 31078482

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study: 27045739

Group type: EXPERIMENTAL
Intervention: Single-session health counseling
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Single-session health counseling and three months of weekly structured group exercise training
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study: 25956283

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1000 IU/day orally
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 23216868

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 165
Study: 16828477

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily for 21 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Estrogen (2 mg daily for 21 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Estrogen+Progestagen (2 mg E(2) + 5 mg medroxyprogesterone acetate daily for 21 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 30
Study: 12492794

Group type: COMPARATOR
Intervention: Epidural block with 15 ml of 0.5% bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psoas compartment block with 30 ml of 0.5% bupivacaine
Number of subjects: 30
Study: 11699358

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 10
Study: 8784087

Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (age- and weight-matched ovulatory women)
Number of subjects: 25
Study: 1458664

Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer 2%
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer 5%
Number of subjects: 157
Study: 6321311

Group type: EXPERIMENTAL
Intervention: Oral ranitidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 6
Study: 30999886

Group type: EXPERIMENTAL
Intervention: Home smartphone urinalysis test (Dip.io)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 999
Study: 27917729

Group type: EXPERIMENTAL
Intervention: Topical triamcinolone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral dapsone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical retinoid
Number of subjects: 40
Study: 25817226

Group type: EXPERIMENTAL
Intervention: Longitudinal eGFR
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Male sex, younger age (<65 years), higher baseline proteinuria
Number of subjects: 1094
Study: 22872427

Group type: EXPERIMENTAL
Intervention: Normal saline and hydroxyethyl starch (Voluven®) dissolved in normal saline (saline)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Balanced crystalloid and colloid solutions (Ringerfundin® and Tetraspan®)
Number of subjects: 36
Study: 21888632

Group type: EXPERIMENTAL
Intervention: Baseline survey prior to a planned cluster randomised intervention
Number of subjects: 7854

Group type: EXPERIMENTAL
Intervention: Children of Balanta ethnic group
Number of subjects: 7854

Group type: EXPERIMENTAL
Intervention: Fula children
Number of subjects: 7854

Group type: EXPERIMENTAL
Intervention: Increasing walking distance to the nearest health centre
Number of subjects: 7854

Group type: EXPERIMENTAL
Intervention: Polygyny
Number of subjects: 7854
Study: 19425821

Group type: EXPERIMENTAL
Intervention: DanShen (Salvia miltiorrhizae)
Number of subjects: 150
Study: 17568837

Group type: EXPERIMENTAL
Intervention: Light polymerization of both the adhesive and resin cement in G-2
Number of subjects: 40

Group type: COMPARATOR
Intervention: G-2 (opaque post)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autopolymerized adhesive in G-4
Number of subjects: 40

Group type: COMPARATOR
Intervention: Middle and apical post/root regions
Number of subjects: 40
Study: 15510807

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 11158015

Group type: EXPERIMENTAL
Intervention: Postnatal estradiol and progesterone replacement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no hormone treatment)
Number of subjects: 30
Study: 10023313

Group type: EXPERIMENTAL
Intervention: High-dose radiotherapy (59.4 Gy in 6.5 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose radiotherapy (45 Gy in 5 weeks)
Number of subjects: 0
Study: 7600396

Group type: EXPERIMENTAL
Intervention: Intraoral technique
Number of subjects: 10

Group type: COMPARATOR
Intervention: Percutaneous technique
Number of subjects: 10
Study: 3289874

Group type: EXPERIMENTAL
Intervention: Piretanid/Captopril
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Piretanid/Urapidil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acebutolol/Piretanid
Number of subjects: 15
Study: 31568905

Group type: EXPERIMENTAL
Intervention: GUIDETM-assisted DBS programming
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional trial-and-error DBS programming
Number of subjects: 10
Study: 28362135

Group type: EXPERIMENTAL
Intervention: cIPV-bOPV-bOPV (I-B-B)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: cIPV-cIPV-bOPV (I-I-B)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All vaccination schedules
Number of subjects: 600
Study: 26422874

Group type: EXPERIMENTAL
Intervention: esmolol 1 mg/kg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: lidocaine 1.0 mg/kg
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.9% NaCl (Control)
Number of subjects: 81
Study: 22921270

Group type: EXPERIMENTAL
Intervention: Baseline body dissatisfaction in girls
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Baseline body dissatisfaction in boys
Number of subjects: 88
Study: 20812949

Group type: EXPERIMENTAL
Intervention: Intermittent recombinant interleukin-2 (rIL-2) with cART
Number of subjects: 179

Group type: COMPARATOR
Intervention: cART alone (control arm)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: rIL-2 received <180 days previously
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: rIL-2 received ≥180 days previously
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: IL-2 arm over time
Number of subjects: 179
Study: 19924605

Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone (15 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-dose metformin (500 mg/day)
Number of subjects: 50
Study: 16824993

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) infusion (7.5 microg/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resting parameters
Number of subjects: 20
Study: 15297687

Group type: COMPARATOR
Intervention: Wheat grass juice (100 mL daily)
Number of subjects: 16
Study: 10708231

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 45

Group type: COMPARATOR
Intervention: 2% carteolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.3% metipranolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All treatments (timolol maleate, carteolol, metipranolol)
Number of subjects: 45
Study: 9496201

Group type: EXPERIMENTAL
Intervention: McCoy blade
Number of subjects: 22

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 22
Study: 8455366

Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment
Number of subjects: 1441

Group type: COMPARATOR
Intervention: AER > or = 28 micrograms/24 hr
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Stratification of all subjects in the secondary cohort
Number of subjects: 1441
Study: 3540874

Group type: EXPERIMENTAL
Intervention: Amfenac 100 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31286908

Group type: EXPERIMENTAL
Intervention: SUPA intervention + usual care
Number of subjects: 372

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 372
Study: 29771568

Group type: EXPERIMENTAL
Intervention: Immediate rewards (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate bonus (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate bonus (Study 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate rewards (Study 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of rewards (Study 5)
Number of subjects: 0
Study: 26739976

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg rocuronium based on corrected body weight (CBW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.2 mg/kg rocuronium based on lean body weight (LBW)
Number of subjects: 40
Study: 24986568

Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants (DOACs)
Number of subjects: 71683

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 71683
Study: 21967443

Group type: EXPERIMENTAL
Intervention: Light effort
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate effort
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous wheeling mode
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stop-go wheeling mode
Number of subjects: 12
Study: 19860554

Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide bleaching
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Soft drink immersion
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Simulated toothbrushing with whitening dentifrice
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Soft drink immersion and bleaching
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Soft drink immersion, bleaching, and toothbrushing
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bleaching and toothbrushing
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 56
Study: 18594373

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 31
Study: 15662233

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 129

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 129
Study: 11843308

Group type: EXPERIMENTAL
Intervention: Goodknight 418A (Malinckrodt, Nancy, France)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Virtuoso LX (Respironics, Nantes, France)
Number of subjects: 12
Study: 10552992

Group type: EXPERIMENTAL
Intervention: Sequential antimicrobial therapy (SAT)
Number of subjects: 89
Study: 8916465

Group type: EXPERIMENTAL
Intervention: Osteoarthritic femoral heads
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control femoral heads
Number of subjects: 12
Study: 1757612

Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol ointment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 204
Study: 6184729

Group type: EXPERIMENTAL
Intervention: Sulprostone (500 micrograms administered i.m. every four or six hours)
Number of subjects: 26
Study: 31736082

Group type: EXPERIMENTAL
Intervention: Stepped-care treatment starting with 14 weekly sessions of manualized CBT
Number of subjects: 269

Group type: COMPARATOR
Intervention: Prolonged CBT
Number of subjects: 269

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 269
Study: 31227777

Group type: EXPERIMENTAL
Intervention: Cognitive training program for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28972790

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 150

Group type: COMPARATOR
Intervention: Right decubitus position
Number of subjects: 150
Study: 25858974

Group type: EXPERIMENTAL
Intervention: TFRL IMT
Number of subjects: 20

Group type: COMPARATOR
Intervention: MTL IMT
Number of subjects: 20
Study: 23363616

Group type: EXPERIMENTAL
Intervention: Home-based physical activity and nutrition program
Number of subjects: 478

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 478
Study: 21185507

Group type: EXPERIMENTAL
Intervention: GTN plus atorvastatin (80 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day) alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: GTN plus placebo
Number of subjects: 36
Study: 19093336

Group type: EXPERIMENTAL
Intervention: 21-gene assay (Oncotype DX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70-gene assay (MammaPrint)
Number of subjects: 0